BMSEED Receives Notice of Patent Approval for Peripheral Nerve Interface Device

Peripheral nerve interface device

We’re excited to share that BMSEED LLC has officially received a Notice of Patent Approval for our latest innovation Peripheral Nerve Interface Device (U.S. Patent No. US12343544B2). This technology, developed by Dr. Oliver Graudejus, Cami C. Rowan, and Dr. Timothy M. Otchy, represents a major step forward in soft bioelectronics and neural interfacing.

Peripheral Nerve Interfacing

The patented device introduces a microclip-based peripheral nerve interface (μcPNI), a microscale system combining a 3D-printed microclip with a soft, stretchable microelectrode array. This design allows the device to wrap gently around small peripheral nerves (less than 200 μm in diameter), creating a stable, long-term bioelectronic connection.

Unlike traditional rigid or bulky nerve cuffs, BMSEED’s μcPNI is biomechanically compliant, moving and flexing naturally with the body’s tissues. This innovation reduces the risk of nerve damage, improves signal fidelity, and opens the door to chronic, high-resolution recording and stimulation of peripheral nerves — all without sutures or adhesives.

Applications in Bioelectronic Medicine

This patent represents a key advancement for bioelectronic therapeutics, a growing field aimed at treating diseases through precise modulation of neural pathways. By enabling stable, selective interfacing with small nerves, the μcPNI could power breakthroughs in:

  • Restoration of motor control in patients with paralysis

  • Advanced prosthetic limb control through high-fidelity nerve mapping

  • Treatment of chronic pain and inflammation via targeted neuromodulation

  • Next-generation research into the peripheral nervous system and its role in health and disease

Soft Materials Engineering

The BMSEED μcPNI leverages decades of interdisciplinary research in soft materials, microfabrication, and neural engineering. The design combines:

  • 3D microprinting for precision microclip fabrication

  • Stretchable gold electrode arrays embedded in elastomeric substrates

  • Microscale clamping mechanisms that self-adjust to variations in nerve size

This approach ensures a secure yet non-invasive interface, allowing researchers and clinicians to interact with delicate neural structures that were previously inaccessible.

BMSEED’s Innovation

This newly approved patent underscores BMSEED’s commitment to developing next-generation bioelectronic interfaces that bridge biology and technology. It complements our growing portfolio of patents in soft, stretchable electronics designed for safe, stable integration with the human body.

“With this innovation, we’re one step closer to realizing a new class of bioelectronic therapies that communicate seamlessly with the nervous system,” said Dr. Oliver Graudejus, Co-Founder and CEO of BMSEED. “Our μcPNI technology provides an unprecedented level of precision and compatibility for long-term peripheral nerve interfacing.”

Patent Information:
Title: Peripheral Nerve Interface Device
Inventors: Oliver Graudejus, Cami C. Rowan, Timothy M. Otchy
Assignee: BMSEED LLC
Patent No.: US12343544B2
Date Granted: July 1, 2025

BMSEED will continue to advance this technology toward preclinical and translational applications in bioelectronic medicine, with the goal of improving patient outcomes through smarter, softer neural interfaces.

Learn more about BMSEED’s work in bioelectronic materials and neural interfacing at bmseed.com, or contact us directly.

Previous
Previous

BMSEED Receives Patent for Soft & Stretchable Microelectrode Arrays with 3D Pocket and Microfluidic Channel

Next
Next

BMSEED at the Göttingen Neuroscience Meeting